Abstract: A luminescent probe and its preparation method and application are provided. The luminescent probe has a steric hindrance group R1 of aliphatic hydrocarbon structure such as adamantane or norborneol, a detection group R2 of nitrobenzyl and its derivative structure, an electron-withdrawing group R3 containing cyano group and an electron-donating group methoxy group. In the presence of HSA or BSA, the detection group is cut off to form a parent structure that exposes atomic oxygen anions and is activated under external light irradiation, the luminescent probe can be used in solution or cells, when detecting HSA or BSA, the luminescent probe has obvious chemiluminescence characteristics, which can sensitively distinguish HSA and BSA, quantitatively analyze HSA and BSA, and determine the mixing ratio of HSA and BSA at the same time, and the luminescent probe has been successfully used for cell fluorescence imaging.

Abstract: A flexible OLED display device includes a flexible display panel and a support member. The flexible display panel includes an active area, an extension portion and a bending portion connecting the active area and the extension portion. The support member is located between the active area and the extension portion. The active area, the support member and the extension portion are stacked, and a predetermined distance is set between the support member and the bending portion in an extending direction parallel to the extension portion.

Abstract: The present invention relates to double stranded oligonucleotides that are complementary to JAK1, leading to modulation of the expression of JAK1. Modulation of JAK1 expression is beneficial for a range of medical disorders including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. Also included are compositions comprising the double stranded oligonucleotide and methods of treatment using the double stranded oligonucleotide.

Abstract: A wireless secure communication method based on RIS-NOMA under complex channel conditions, the method including: firstly, an intelligent surface is assume to be disposed between the base station and legitimate NOMA users, and between the base station and eavesdroppers; the signal to interference plus distortion noise ratio (SIDNR) for the legitimate NOMA user and the eavesdropper is calculated in the presence of RHI in the system; secondly, considering shadow fading and to simplify the overly complex calculation process, the probability density function and cumulative distribution function of the shadow fading are approximated; finally, the outrage probability and intercept probability of the legitimate users and eavesdroppers are calculated.

Abstract: The present invention relates to a gapmer oligonucleotide comprising at least one phosphorodithioate internucleoside linkage of formula (I) as defined in the description and in the claims. The oligonucleotide of the invention can be used as a medicement.

Abstract: Described are antisense oligonucleotides comprising one or more ?-L-threofuranosyl (TNA) nucleosides as well as methods to modulate the properties of antisense oligonucleotides by the introduction of TNA nucleosides. These are particularly applicable for antisense gapmer oligonucleotides.

Abstract: The present invention relates to antisense oligonucleotides which are complementary to conserved TDP-43 binding sites on pre-mRNA transcripts, which are capable of restoring RNA binding protein function in the processing of multiple independent mRNAs in TDP-43 depleted cells.

Abstract: The present invention relates to antisense oligonucleotides which are complementary to conserved TDP-43 binding sites on pre-mRNA transcripts, which are capable of restoring RNA binding protein function in the processing of multiple independent mRNAs in TDP-43 depleted cells.

Abstract: The present invention relates to a compound of formula (II) or (IIb) Wherein X, Y, Rx, Ry, R5 and Nu are as defined in the description and in the claims. The compound of formula (II) can be used in the manufacture of oligonucleotides.

Abstract: The present invention relates to an oligonucleotide comprising at least one phosphorodithioate internucleoside linkage of formula (I) (I) as defined in the description and in the claim. The oligonucleotide of the invention can be used as a medicement.

Abstract: The present invention relates to antisense oligonucleotides which are complementary to conserved TDP-43 binding sites on pre-mRNA transcripts, which are capable of restoring RNA binding protein function in the processing of multiple independent mRNAs in TDP-43 depleted cells.

Abstract: The present invention relates to an oligonucleotide comprising at least one phosphorotrithioa to internucleoside linkage of formula (I), wherein (A1), (A2) and R are as defined in the description and in the claim. The oligonucleotide of the invention can be used as a medicament.

Abstract: The present invention relates to an oligonucleotide comprising at least one phosphorotrithioate internucleoside linkage of formula (I) as defined herein. The oligonucleotide of the invention can be used as a medicament.

Abstract: The present invention relates to a compound of formula (II) or (IIb) Wherein X, Y, Rx, Ry, R5 and Nu are as defined in the description and in the claims. The compound of formula (II) can be used in the manufacture of oligonucleotides.

Abstract: A method may add whey to high calcium papermaking industrial wastewater blended and pre-acidification treatment to promote anaerobic reaction and inhibit calcification. The method includes, before anaerobic treatment of papermaking wastewater, mixing whey wastewater with the papermaking wastewater. The method also includes pre-treating the papermaking wastewater by acidification to stabilize the papermaking wastewater prior to entering an anaerobic reaction system.

Abstract: To promote anaerobic digestion and delay calcification, one or more signal molecules are used to regulate the microenvironment of anaerobic granular sludge. In the process of anaerobic granular sludge treatment of papermaking wastewater, AHLs (N-acyl Hyperserine Lactones) are added to papermaking wastewater before the papermaking wastewater enters the anaerobic reactor. This may occur when the proportion of microorganism in anaerobic granular sludge VSS/TSS is less than 0.6. Further, the addition of the one or more signal molecules changes the community structure of the bacteria and methanogens, promoting anaerobic digestion and delay calcification. Additionally, the microenvironment of granular sludge is regulated by adding one or more micro-signal molecules to improve the number of bacteria susceptible to calcification, improve the anaerobic digestion rate of sludge that has not been calcified, and delay the calcification rate.

Abstract: A method may add whey to high calcium papermaking industrial wastewater blended and pre-acidification treatment to promote anaerobic reaction and inhibit calcification. The method includes, before anaerobic treatment of papermaking wastewater, mixing whey wastewater with the papermaking wastewater. The method also includes pre-treating the papermaking wastewater by acidification to stabilize the papermaking wastewater prior to entering an anaerobic reaction system.

Abstract: The present invention relates to chiral phosphoramidites represented by formula (Ia) or formula (Ib) as novel monomers for the synthesis of stereodefined phosphorothioate MOE oligonucleotides. Furthermore, the present invention relates to a method for synthesizing stereodefined phosphorothioate MOE oligonucleotides using said novel chiral phosphoramidites.

Abstract: The present invention relates to an oligonucleotide comprising at least one phosphorodithioate internucleoside linkage of formula (I) (I) as defined in the description and in the claim. The oligonucleotide of the invention can be used as a medicament.

Abstract: The present invention relates to a gapmer oligonucleotide comprising at phosphorodithioate internucleoside linkage of formula (I) as defined in the description and in the claims. The oligonucleotide of the invention can be used as a medicament.